<scp>DNA</scp> vaccine <scp>ROP</scp>29 from <i>Toxoplasma gondii</i> containing R848 enhances protective immunity in mice

Lü, Gang; Zhou, Jian; Zhao, Ying; Wang, Lin

doi:10.1111/pim.12578

Cited by 11 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Supplementing this GRA14 DNA vaccine with a calcium phosphate nanoparticle adjuvant increased the T. gondii -specific IgG1 and IgG2a antibody responses as well as lymphocyte proliferation, albeit failing to result in enhanced survival [ 24 ]. Vaccines expressing the B and T cell epitopes of ROP29 adjuvanted with resiquimod (R848), an agonist of Toll-like receptor (TLR) 7/8, enhanced the antibody responses and Th1 cytokine production as well as further reducing the brain cyst burden compared to the unadjuvanted control group post-challenge with PRU strain [ 25 ]. A multi-epitope ROP8 vaccine co-delivered with the genetic adjuvant IL-12 promoted antibody production and Th1 immune responses, with a marginal increase in survival [ 26 ].…”

Section: Vaccine Platforms Against T Gondiimentioning

confidence: 99%

Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development

Chu

Quan

2021

Vaccines

View full text Add to dashboard Cite

Toxoplasmosis, caused by the apicomplexan parasite Toxoplasma gondii, is one of the most damaging parasite-borne zoonotic diseases of global importance. While approximately one-third of the entire world’s population is estimated to be infected with T. gondii, an effective vaccine for human use remains unavailable. Global efforts in pursuit of developing a T. gondii vaccine have been ongoing for decades, and novel innovative approaches have been introduced to aid this process. A wide array of vaccination strategies have been conducted to date including, but not limited to, nucleic acids, protein subunits, attenuated vaccines, and nanoparticles, which have been assessed in rodents with promising results. Yet, translation of these in vivo results into clinical studies remains a major obstacle that needs to be overcome. In this review, we will aim to summarize the current advances in T. gondii vaccine strategies and address the challenges hindering vaccine development.

show abstract

Section: Vaccine Platforms Against T Gondiimentioning

confidence: 99%

Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development

Chu

Quan

2021

Vaccines

View full text Add to dashboard Cite

show abstract

“…Only, few studies have, thus, far focused on the cat vaccination. The use of a live mutant bradyzoite named T-263 was the first trial in which kittens were vaccinated [31]. After the oral inoculation, most of the kittens generated protective immunity; oocyst shedding was successfully prevented in 84% of the cats when challenged with the T. gondii parasite [31,32].…”

Section: Vaccine In Cats and Livestockmentioning

confidence: 99%

“…The use of a live mutant bradyzoite named T-263 was the first trial in which kittens were vaccinated [31]. After the oral inoculation, most of the kittens generated protective immunity; oocyst shedding was successfully prevented in 84% of the cats when challenged with the T. gondii parasite [31,32]. Unfortunately, T-263 has many disadvantages, including the need to use live bradyzoites and high costs [33].…”

Section: Vaccine In Cats and Livestockmentioning

confidence: 99%

Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: A mini-review

et al. 2019

View full text Add to dashboard Cite

Despite the significant progress in the recent efforts toward developing an effective vaccine against toxoplasmosis, the search for new protective vaccination strategy still remains a challenge and elusive goal because it becomes the appropriate way to prevent the disease. Various experimental approaches in the past few years showed that developing a potential vaccine against the disease can be achievable. The combination of multi-epitopes expressing different stages of the parasite life cycle has become an optimal strategy for acquiring a potent, safe, and effective vaccine. Epitope-based vaccines have gained attention as alternative vaccine candidates due to their ability of inducing protective immune responses. This mini-review highlights the current status and the prospects of Toxoplasma gondii vaccine development along with the application of epitope-based vaccine in the future parasite immunization as a novel under development and evaluation strategy.

show abstract

“…Eliciting strong cellular and humoral immunity against T. gondii, an effective vaccine target should be highly immunogenic and improbable to induce autoimmune and allergic reactions (15). Numerous vaccine targets have been evaluated in different types of vaccines against T. gondii, and these targets mainly include dense granule proteins (16), surface proteins (17), rhoptry proteins (18), microneme proteins (19), etc. However, these vaccine targets cannot fully protect against the virulent challenge, and a suitable vaccine is still unavailable (20)(21)(22).…”

Section: Introductionmentioning

confidence: 99%

“…With the emergence of new antigens, adjuvants, and therapeutics, vaccines against toxoplasmosis evolved noticeably. In recent years, many studies have evaluated the immune protection triggered by DNA vaccines encoding a single or multicomponent antigen against toxoplasmosis in a mice model (17,18,31). As a DNA vaccine vector, pVAX1 is approved by the Food and Drug Administration (FDA).…”

Section: Introductionmentioning

confidence: 99%

With Chitosan and PLGA as the Delivery Vehicle, Toxoplasma gondii Oxidoreductase-Based DNA Vaccines Decrease Parasite Burdens in Mice

Cao

Gao

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Toxoplasma gondii (T. gondii) is an intracellular parasitic protozoan that can cause serious public health problems. However, there is no effectively preventive or therapeutic strategy available for human and animals. In the present study, we developed a DNA vaccine encoding T. gondii oxidoreductase from short-chain dehydrogenase/reductase family (TgSDRO-pVAX1) and then entrapped in chitosan and poly lactic-co-glycolic acid (PLGA) to improve the efficacy. When encapsulated in chitosan (TgSDRO-pVAX1/CS nanospheres) and PLGA (TgSDRO-pVAX1/PLGA nanospheres), adequate plasmids were loaded and released stably. Before animal immunizations, the DNA vaccine was transfected into HEK 293-T cells and examined by western blotting and laser confocal microscopy. Th1/Th2 cellular and humoral immunity was induced in immunized mice, accompanied by modulated secretion of antibodies and cytokines, promoted the maturation and MHC expression of dendritic cells, and enhanced the percentages of CD4+ and CD8+ T lymphocytes. Immunization with TgSDRO-pVAX1/CS and TgSDRO-pVAX1/PLGA nanospheres conferred significant immunity with lower parasite burden in the mice model of acute toxoplasmosis. Furthermore, our results also lent credit to the idea that TgSDRO-pVAX1/CS and TgSDRO-pVAX1/PLGA nanospheres are substitutes for each other. In general, the current study proposed that TgSDRO-pVAX1 with chitosan or PLGA as the delivery vehicle is a promising vaccine candidate against acute toxoplasmosis.

show abstract

DNA vaccine ROP29 from Toxoplasma gondii containing R848 enhances protective immunity in mice

Abstract: R848 could improve the productions of IL-12 and IFN-γ, thus enhancing the immune responses stimulated by the pROP29 DNA vaccine.

Cited by 11 publications

References 35 publications

Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development

Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development

Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: A mini-review

With Chitosan and PLGA as the Delivery Vehicle, Toxoplasma gondii Oxidoreductase-Based DNA Vaccines Decrease Parasite Burdens in Mice

Contact Info

Product

Resources

About